Vanguard Group
NBIX icon

Vanguard Group’s Neurocrine Biosciences NBIX Stock Holding History

Quarter Market Value Status Shares Shares
Change %
Trade Value Portfolio Weight Portfolio Position
2025
Q2
$1.23B Sell
9,807,066
-134,821
-1% -$16.9M 0.02% 604
2025
Q1
$1.1B Sell
9,941,887
-177,754
-2% -$19.7M 0.02% 611
2024
Q4
$1.38B Buy
10,119,641
+122,681
+1% +$16.7M 0.02% 564
2024
Q3
$1.15B Sell
9,996,960
-59,486
-0.6% -$6.85M 0.02% 613
2024
Q2
$1.38B Buy
10,056,446
+125,520
+1% +$17.3M 0.03% 540
2024
Q1
$1.37B Buy
9,930,926
+220,598
+2% +$30.4M 0.03% 558
2023
Q4
$1.28B Buy
9,710,328
+150,485
+2% +$19.8M 0.03% 557
2023
Q3
$1.08B Sell
9,559,843
-10,875
-0.1% -$1.22M 0.03% 574
2023
Q2
$903M Sell
9,570,718
-26,814
-0.3% -$2.53M 0.02% 649
2023
Q1
$971M Buy
9,597,532
+257,237
+3% +$26M 0.02% 601
2022
Q4
$1.12B Buy
9,340,295
+339,332
+4% +$40.5M 0.03% 541
2022
Q3
$956M Buy
9,000,963
+96,489
+1% +$10.2M 0.03% 575
2022
Q2
$868M Buy
8,904,474
+127,016
+1% +$12.4M 0.02% 609
2022
Q1
$823M Sell
8,777,458
-10,533
-0.1% -$987K 0.02% 697
2021
Q4
$748M Sell
8,787,991
-100,479
-1% -$8.56M 0.02% 775
2021
Q3
$852M Sell
8,888,470
-96,151
-1% -$9.22M 0.02% 706
2021
Q2
$874M Buy
8,984,621
+155,346
+2% +$15.1M 0.02% 702
2021
Q1
$859M Buy
8,829,275
+492,010
+6% +$47.8M 0.02% 682
2020
Q4
$799M Buy
8,337,265
+175,732
+2% +$16.8M 0.02% 668
2020
Q3
$785M Sell
8,161,533
-317,806
-4% -$30.6M 0.03% 593
2020
Q2
$1.03B Sell
8,479,339
-24,349
-0.3% -$2.97M 0.04% 489
2020
Q1
$736M Buy
8,503,688
+186,791
+2% +$16.2M 0.03% 526
2019
Q4
$894M Buy
8,316,897
+100,511
+1% +$10.8M 0.03% 578
2019
Q3
$740M Buy
8,216,386
+99,017
+1% +$8.92M 0.03% 625
2019
Q2
$685M Sell
8,117,369
-38,488
-0.5% -$3.25M 0.03% 663
2019
Q1
$719M Buy
8,155,857
+76,039
+0.9% +$6.7M 0.03% 615
2018
Q4
$577M Buy
8,079,818
+307,582
+4% +$22M 0.03% 643
2018
Q3
$956M Buy
7,772,236
+204,065
+3% +$25.1M 0.04% 537
2018
Q2
$743M Buy
7,568,171
+257,865
+4% +$25.3M 0.03% 598
2018
Q1
$606M Buy
7,310,306
+184,913
+3% +$15.3M 0.03% 653
2017
Q4
$553M Buy
7,125,393
+101,951
+1% +$7.91M 0.02% 707
2017
Q3
$430M Buy
7,023,442
+101,148
+1% +$6.2M 0.02% 786
2017
Q2
$318M Buy
6,922,294
+186,329
+3% +$8.57M 0.02% 946
2017
Q1
$292M Buy
6,735,965
+293,755
+5% +$12.7M 0.02% 979
2016
Q4
$249M Buy
6,442,210
+153,953
+2% +$5.96M 0.01% 1030
2016
Q3
$318M Buy
6,288,257
+208,888
+3% +$10.6M 0.02% 824
2016
Q2
$276M Sell
6,079,369
-7,353
-0.1% -$334K 0.02% 868
2016
Q1
$241M Buy
6,086,722
+148,691
+3% +$5.88M 0.02% 922
2015
Q4
$336M Buy
5,938,031
+175,693
+3% +$9.94M 0.02% 741
2015
Q3
$229M Buy
5,762,338
+399,910
+7% +$15.9M 0.02% 914
2015
Q2
$256M Buy
5,362,428
+1,419,573
+36% +$67.8M 0.02% 904
2015
Q1
$157M Buy
3,942,855
+1,581,276
+67% +$62.8M 0.01% 1183
2014
Q4
$52.8M Buy
2,361,579
+77,743
+3% +$1.74M ﹤0.01% 1806
2014
Q3
$35.8M Buy
2,283,836
+68,679
+3% +$1.08M ﹤0.01% 1963
2014
Q2
$32.9M Sell
2,215,157
-5,985
-0.3% -$88.8K ﹤0.01% 2033
2014
Q1
$35.8M Buy
2,221,142
+334,323
+18% +$5.38M ﹤0.01% 1973
2013
Q4
$17.6M Buy
1,886,819
+59,305
+3% +$554K ﹤0.01% 2213
2013
Q3
$20.7M Buy
1,827,514
+19,130
+1% +$217K ﹤0.01% 2098
2013
Q2
$24.2M Buy
+1,808,384
New +$24.2M ﹤0.01% 2003